key: cord-0964204-0u3uka3w
authors: Levy, Jerrold H.; Iba, Toshiaki; Olson, Lyra B.; Corey, Kristen M.; Ghadimi, Kamrouz; Connors, Jean M.
title: COVID‐19: Thrombosis, thromboinflammation, and anticoagulation considerations
date: 2021-07-20
journal: Int J Lab Hematol
DOI: 10.1111/ijlh.13500
sha: 6f94426bf791e54e24b52eed3281d20f29a78086
doc_id: 964204
cord_uid: 0u3uka3w

Vascular endothelial injury is a hallmark of acute infection at both the microvascular and macrovascular levels. The hallmark of SARS‐CoV‐2 infection is the current COVID‐19 clinical sequelae of the pathophysiologic responses of hypercoagulability and thromboinflammation associated with acute infection. The acute lung injury that initially occurs in COVID‐19 results from vascular and endothelial damage from viral injury and pathophysiologic responses that produce the COVID‐19–associated coagulopathy. Clinicians should continue to focus on the vascular endothelial injury that occurs and evaluate potential therapeutic interventions that may benefit those with new infections during the current pandemic as they may also be of benefit for future pathogens that generate similar thromboinflammatory responses. The current Accelerating COVID‐19 Therapeutic Interventions and Vaccines (ACTIV) studies are important projects that will further define our management strategies. At the time of writing this report, two mRNA vaccines are now being distributed and will hopefully have a major impact on slowing the global spread and subsequent thromboinflammatory injury we see clinically in critically ill patients.

that initially occurs in COVID-19 results from vascular and endothelial damage from viral injury and pathophysiologic responses that produce the COVID-19-associated coagulopathy. Clinicians should continue to focus on the vascular endothelial injury that occurs and evaluate potential therapeutic interventions that may benefit those with new infections during the current pandemic as they may also be of benefit for future pathogens that generate similar thromboinflammatory responses. The current Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) studies are important projects that will further define our management strategies. At the time of writing this report, two mRNA vaccines are now being distributed and will hopefully have a major impact on slowing the global spread and subsequent thromboinflammatory injury we see clinically in critically ill patients.

anticoagulant therapy, coagulopathy, COVID-19, disseminated intravascular coagulation, endothelial cell, thrombosis

In response to acute infections, a systemic inflammatory response syndrome ensues that has been previously described in acute bacterial infections producing septic shock. One of the critical complications of sepsis and septic shock is coagulopathy, defined as the laboratory-based findings of disseminated intravascular coagulation (DIC). 3, 4 Multiorgan failure and death can occur during septic shock, and patients with DIC have a higher mortality. The coagulopathy due to sepsis described as DIC can be hemorrhagic and/or thrombotic and varies depending on the type of infection, associated organ injury, and host inflammatory responses. 2, 3 The hypercoagulability of acute infection is associated with an increased fibrinogen level and thrombin generation that occurs in the milieu of microorganism induced acute endothelial injury that decreases levels of circulating anticoagulants, including protein C and antithrombin. 2 As part of the progression of the infection, additional coagulation factors, including platelets, are consumed, and coagulation tests, including prothrombin times and potentially partial thromboplastin times, are prolonged. Therapy also depends on the course of the disease as it may progress from an initial hypercoagulability, the sine qua non of COVID-19 infection, to subsequent DIC in prolonged intensive care unit stays and due to secondary bacterial infections, such as ventilator-associated pneumonia. 5 

Like all infection-related coagulopathies, SARS-CoV-2-induced infection is associated with a high incidence of thromboembolic complications, as shown in Table 1 . 6 As previously described and depicted in Figure 1 , the acute thromboinflammatory/immunothrombotic response following SARS-CoV-2 infection impairs tissue TA B L E 1 COVID-19: thrombosis data on anticoagulation prophylaxis microcirculation causing injury initially in the lung that can cascade to other organs. 6 The inflammatory response that occurs due to the lack of prior immunity releases multiple cytokines that may produce a systemic inflammatory response syndrome, often described as a cytokine storm in COVID-19. 7 Cytokines, including tumor necrosis factor (TNF)α, interleukin-6, and interleukin-8, are released. 8 Ranucci reported that increased fibrinogen production correlated with interleukin six levels in COVID-19 patients with acute lung injury and mechanical ventilation demonstrating the link between inflammation and hypercoagulability in these patients. 9 However, interleukin-6 levels in septic patients due to bacterial infections are as high as 1000 pg/mL compared with the more modest interleukin- COVID-19 is also associated with relative deficiency of ADAMTS13, the critical cleavage enzyme for von Willebrand factor, and as a result results in larger, more procoagulant multimers of von Willebrand factor remaining in the circulation. 13 Cell death and necrosis likely release multiple antigenic epitopes to the primed immune system that cause additional autoimmune responses that include the generation of antiphospholipid antibodies, and activate humoral amplification cascades including contact activation and complement. 8 As previously described, the clinical manifestations of this virally induced acute lung injury produce an adult respiratory distress syndrome (ARDS) with acute hypoxemia, increased capillary permeability, and the characteristic findings of ground-glass appearance on radiographic imaging due to increased capillary permeability and pulmonary edema. 14 It is not surprising that without any specific antiviral therapies, the unchecked disease process in COVID-19 and SARS yielded thrombi with rates over two times higher than in H1N1 patients on biopsies and/or postmortems.

Thromboinflammation is defined as thrombosis due to underlying inflammatory processes. This can occur in a wide range of clinical scenarios including acute infection, reperfusion injury associated with acute shock and resuscitation, and blood nonendothelial surface interfacing in biomaterial-induced mechanical cardiopulmonary support devices. 1 The hallmark of thromboinflammation is microvascular thrombosis-associated inflammation, which is well-recognized in the context of sepsis. 19 The pathophysiology of thromboinflammation is due to vascular endothelial injury, with subsequent loss of endothelial and glycocalyx vascular interfaces that activate multiple cellular and humoral inflammatory system amplification pathways. 1, 20 The humoral components of thromboinflammation also activate coagulation pathways, including contact factor activation, complement, and the fibrinolytic sys- Clinical thrombosis in COVID-19-associated coagulopathy is more commonly thrombotic than in sepsis-induced coagulopathy, with a number of studies reporting the increased risk of thromboembolic events in hospitalized COVID-19 patients as shown in Table 1 .

One of the issues when reviewing the early literature from China is the consideration that many of the initial reported cases were in patients who did not receive thromboprophylaxis. The more recent risk of thromboembolic complications in patients receiving standard dosing of both low molecular heparin and unfractionated heparin is shown in Table 1 .

Some of the representative studies shown in Table 1 23 Other studies in ARDS that compared COVID-19 patients to other critically ill ICU patients also report increased thromboembolic event rates of 11.7% in COVID-19-positive patients vs.

2.1% in the non-COVID-19 ICU cohort. 24 Additional reports from

France noted the incidence of pulmonary emboli in ICU COVID-19

patients to be three times higher than other critically ill patients with pneumonia (20.6% vs 6.1%). 25 It is important to consider that thrombosis associated with COVID-19 differs among reported studies particularly based on whether surveillance imaging was used to detect clinically silent thrombosis. Pooled data suggest an 8% pulmonary emboli incidence, but multiple factors may limit the interpretation.

Fibrinolytic shutdown (also called fibrinolysis inhibition) is a term popularized in trauma patients. 26 Diagnosed by viscoelastic testing using thromboelastography (TEG systems) or thromboelastometry (ROTEM systems), it has also been reported to describe fibrinolysis inhibition in COVID-19 as a risk factor for potential thromboembolic events. Fibrinolytic shutdown may be in part due to increased release of plasminogen activator inhibitor 1 (PAI-1), a finding that has been reported as a host defense response to infection, and increased PAI-1 and tPA levels have been reported in COVID-19 patients.

Creel 

Multiple guidance and guideline documents have published anticoagulation dosing strategies for inpatients, using heparin as the primary anticoagulant. Whether unfractionated heparin or low-molecularweight heparin is used depends on multiple factors, including renal function. The benefit of low-molecular-weight heparin is standard dosing without the need to titrate and/or monitor coagulation levels.

The optimal thromboprophylaxis strategy for hospitalized patients with COVID-19 remains to be determined. 28 fibrinogen. 30 Retrospective data from one US institution in which all hospitalized patients received a standard dose thromboprophylaxis regardless of disease severity noted higher rates of thrombosis in critically ill ICU patients compared with patients on the ward, although the rate was lower than those reported from some European centers where a 25% lower dose of low-molecular-weight heparin was standardly used. 30 The current Accelerating COVID-19 ACTIV studies are important projects that will further define our management strategies. Of 

Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Jerrold H. Levy https://orcid.org/0000-0003-3766-4962

Toshiaki Iba https://orcid.org/0000-0002-0255-4088

Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms

Immunohaemostasis: a new view on haemostasis during sepsis. Ann Intensive Care

Differential diagnoses for sepsisinduced disseminated intravascular coagulation: communication from the SSC of the ISTH

Diagnosis and management of sepsis-induced coagulopathy and disseminated intravascular coagulation

COVID-19 and its implications for thrombosis and anticoagulation

Coagulopathy in COVID-19

An inflammatory cytokine signature predicts COVID-19 severity and survival

The coagulopathy, endotheliopathy, and vasculitis of COVID-19

The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome

The unique characteristics of COVID-19 coagulopathy

Endothelial cell infection and endotheliitis in COVID-19

Vascular injury in acute infections and COVID-19: everything old is new again

The ADAMTS13-von Willebrand factor axis in COVID-19 patients

Coagulopathy of coronavirus disease 2019

Hypercoagulability and coronavirus disease 2019-associated hypoxemic respiratory failure: mechanisms and emerging management paradigms

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19

The pulmonary vascular lesions of the adult respiratory distress syndrome

Lung histopathology in coronavirus disease 2019 as compared with severe acute respiratory syndrome and H1N1 influenza: a systematic review

Inflammation and thrombosis: roles of neutrophils, platelets and endothelial cells and their interactions in thrombus formation during sepsis

Protection of the endothelial glycocalyx by antithrombin in an endotoxin-induced rat model of sepsis

Derangement of the endothelial glycocalyx in sepsis

Thromboinflammation and the hypercoagulability of COVID-19

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Pulmonary embolism in patients with COVID-19: awareness of an increased prevalence

Defining trauma-induced coagulopathy with respect to future implications for patient management: communication from the SSC of the ISTH

Fibrinolysis shutdown and thrombosis in a COVID-19 ICU

Scientific and Standardization Committee communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19

Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study

VTE in ICU patients with COVID-19

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

The developing balance of thrombosis and hemorrhage in pediatric surgery: clinical implications of age-related changes in hemostasis

Incidence of venous thromboembolism in hospitalized patients with COVID-19

COVID-19: Thrombosis, thromboinflammation, and anticoagulation considerations